Vertex Pharma stock rises as FDA decision nears

Published on 11/12/2026 at 16:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharma stock is drawing attention ahead of a key FDA decision. Revenue growth and higher guidance broaden the investment case beyond cystic fibrosis.

Growth And FDA Catalyst

Vertex raised its full-year 2026 revenue guidance after third-quarter revenue increased.
The November 30 FDA target date for povetacicept could open Vertex's first commercial nephrology franchise.
Higher acquisition and commercialization costs reduced GAAP earnings despite stronger sales.

Vertex Pharma, US92532F1003, Illustration mit AI erstellt.

Vertex Pharmaceuticals is approaching a key regulatory date after reporting stronger third-quarter sales and raising its full-year outlook. The company said on November 2 that revenue for the quarter ended September 30 increased 12 percent year over year to 3.44 billion US dollars, according to its third-quarter financial release.

Growth Broadens Beyond Cystic Fibrosis

Cystic fibrosis products remained the main revenue source, generating 3.27 billion US dollars in the quarter. Newer products also contributed, with CASGEVY revenue of 99.2 million US dollars, JOURNAVX revenue of 58.3 million US dollars and PALSONIFY revenue of 10.1 million US dollars.

Vertex lifted its 2026 total revenue guidance to 13.15 billion to 13.25 billion US dollars from 13.1 billion to 13.2 billion previously. The outlook includes at least 500 million US dollars from CASGEVY and JOURNAVX combined and 40 million to 50 million US dollars from PALSONIFY.

Reported earnings faced pressure from the Crinetics Pharmaceuticals acquisition and broader commercial investment. GAAP net income fell to 653.6 million US dollars from 1.08 billion US dollars a year earlier, while non-GAAP net income was 1.21 billion US dollars compared with 1.24 billion US dollars.

FDA Date Shapes Near-Term Focus

The U.S. Food and Drug Administration has assigned November 30 as the PDUFA target action date for povetacicept in IgA nephropathy. Vertex's application is under priority review and is supported by interim Phase 3 RAINIER results. If approved, povetacicept would become the company's first commercialized nephrology therapy.

Vertex Pharmaceuticals stock traded at 491.55 euros on Lang & Schwarz at 16:15 CET on Thursday, November 12, 2026. That was 1.30 percent above the 485.25-euro quote cited in the previous report published on November 11; this separate report-to-report comparison is not a Xetra session comparison.

For investors, the raised outlook offers evidence of expanding commercial contributions, while the upcoming FDA decision represents a binary regulatory catalyst. The company is also increasing spending to support the renal franchise, the Crinetics integration and the JOURNAVX launch.